信邦制药信披迟滞引发股价暴跌，受损投资者切莫错过维权机会

Group 1 - The core issue revolves around the delayed disclosure of information by Xinbang Pharmaceutical, which was accused of bribery and subsequently faced a significant drop in stock price, falling nearly 20% within two days after the announcement [1][2][4] - The company announced on December 10 that it was being prosecuted for bribery, leading to a stock price decline of 9.88% on the following day, with a cumulative drop close to 20% by December 12 [1][3] - There is a concern regarding a "information disclosure vacuum" period, as the company did not disclose earlier investigations related to its actual controller, which raises questions about the timeliness of its disclosures [4][5] Group 2 - Following the stock price decline, Xinbang Pharmaceutical received inquiries from investors and regulatory bodies regarding the unusual stock price movements prior to the announcement [2][5] - The controversy is linked to a merger case from ten years ago, with the company's fundamentals already showing signs of decline before the bribery allegations surfaced [2][5] - A compensation process has been initiated for investors who purchased shares before December 10, 2025, and sold or still hold them after December 11, 2025, resulting in losses [3][5]